Clinical Trial Update: SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC [NA]

View source ↗

Summary

An ongoing clinical trial evaluating a regimen of short-course radiotherapy (SCRT) followed by Nal-IRI XELOX and Sintilimab as total neoadjuvant therapy for hig…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Adenocarcinoma
• Rectal Cancer

Drugs mentioned

• Onivyde (irinotecan hydrochloride liposome injection)
• Tyvyt (Sintilimab)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Rectal Cancer, Adenocarcinoma | NA | Status: RECRUITING